These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8894076)

  • 41. Alpidem in the treatment of panic disorder.
    Schneier FR; Carrasco JL; Hollander E; Campeas R; Fallon B; Saoud JB; Feerick J; Liebowitz MR
    J Clin Psychopharmacol; 1993 Apr; 13(2):150-3. PubMed ID: 8096527
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Cholecystokinin antagonists: anxiolytic drugs of the future].
    Bourin M; Bradwejn J
    Pathol Biol (Paris); 1992 Mar; 40(3):215-7. PubMed ID: 1608663
    [No Abstract]   [Full Text] [Related]  

  • 43. Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy.
    Carter CS; Fawcett J; Hertzman M; Papp LA; Jones W; Patterson WM; Swinson RP; Weise CC; Maddock RJ; Denahan AQ
    J Clin Psychiatry; 1995 May; 56(5):202-10. PubMed ID: 7737960
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Panic and agoraphobia's sequence of improvement during pharmacotherapy.
    Klein DF
    Compr Psychiatry; 1992; 33(3):220. PubMed ID: 1591916
    [No Abstract]   [Full Text] [Related]  

  • 45. Adinazolam sustained-release treatment of panic disorder: a double-blind study.
    Davidson JR; Beitman B; Greist JH; Maddock RJ; Lewis CP; Sheridan AQ; Carter C; Krishnan KR; Liebowitz MR; Haack DG
    J Clin Psychopharmacol; 1994 Aug; 14(4):255-63. PubMed ID: 7962681
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Contributing factors associated with agoraphobia.
    Goldberg C
    Psychol Rep; 1993 Feb; 72(1):192-4. PubMed ID: 8451355
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Peripheral cholecystokinin A and cholecystokinin B receptors mediate stimulation of gastric pepsinogen and acid secretion following intracerebroventricular injection of cholecystokinin-8-sulphate.
    Blandizzi C; Lazzeri G; Carignani D; Colucci R; Baschiera F; Tognetti M; Placanica G; Del Tacca M
    Ital J Gastroenterol Hepatol; 1999; 31(6):440-8. PubMed ID: 10575559
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tiagabine improves panic and agoraphobia in panic disorder patients.
    Zwanzger P; Baghai TC; Schüle C; Minov C; Padberg F; Möller HJ; Rupprecht R
    J Clin Psychiatry; 2001 Aug; 62(8):656-7. PubMed ID: 11561942
    [No Abstract]   [Full Text] [Related]  

  • 49. Treatment of panic disorder and agoraphobia with clonazepam.
    Spier SA; Tesar GE; Rosenbaum JF; Woods SW
    J Clin Psychiatry; 1986 May; 47(5):238-42. PubMed ID: 3700341
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Valproate treatment of panic disorder and lactate-induced panic attacks.
    Keck PE; Taylor VE; Tugrul KC; McElroy SL; Bennett JA
    Biol Psychiatry; 1993 Apr; 33(7):542-6. PubMed ID: 8513040
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Onset of panic disorder.
    Faravelli C; Pallanti S; Biondi F; Paterniti S; Scarpato MA
    Am J Psychiatry; 1992 Jun; 149(6):827-8. PubMed ID: 1590502
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Panic disorder and agoraphobia: what is effective?].
    Bandelow B; Sievert K; Röthemeyer M; Hajak G; Broocks A; Rüther E
    Fortschr Neurol Psychiatr; 1995 Nov; 63(11):451-64. PubMed ID: 8575719
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reversible monoamine oxidase-A inhibitors in panic disorder.
    Bakish D; Saxena BM; Bowen R; D'Souza J
    Clin Neuropharmacol; 1993; 16 Suppl 2():S77-82. PubMed ID: 8313401
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cholecystokinin tetrapeptide-induced calcium mobilization in T cells of patients with panic disorder, major depression, or schizophrenia.
    Akiyoshi J; Isogawa K; Tsutsumi T; Kasturagi S; Kohno K; Furuta M; Yamamoto Y; Yamada K; Fujii I
    Biol Psychiatry; 1997 Jul; 42(2):151-4. PubMed ID: 9209734
    [No Abstract]   [Full Text] [Related]  

  • 55. Pramipexole augmentation in panic with agoraphobia.
    Marazziti D; Presta S; Pfanner C; Dell'Osso L; Cassano GB
    Am J Psychiatry; 2001 Mar; 158(3):498-9. PubMed ID: 11230001
    [No Abstract]   [Full Text] [Related]  

  • 56. Agoraphobia and panic attacks complicated by primary aldosteronism improved by treatment with eplerenone: a case report.
    Kijima R; Tesen H; Igata R; Okamoto N; Yoshimura R
    BMC Psychiatry; 2023 Oct; 23(1):787. PubMed ID: 37891534
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomised, double blind, placebo controlled crossover study of the cholecystokinin 2 antagonist L-365,260 as an adjunct to strong opioids in chronic human neuropathic pain.
    McCleane GJ
    Neurosci Lett; 2003 Feb; 338(2):151-4. PubMed ID: 12566175
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MDMA (Ecstasy) precipitation of panic disorder.
    Pallanti S; Mazzi D
    Biol Psychiatry; 1992 Jul; 32(1):91-5. PubMed ID: 1356491
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lactate-induced panic and beta-adrenergic blockade.
    Yeragani VK; Pohl R; Balon R
    Psychiatry Res; 1990 Apr; 32(1):93-4. PubMed ID: 2349314
    [No Abstract]   [Full Text] [Related]  

  • 60. Olanzapine and panic attacks.
    Etxebeste M; Aragüés E; Malo P; Pacheco L
    Am J Psychiatry; 2000 Apr; 157(4):659-60. PubMed ID: 10739446
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.